VCM
CCCC icon

Voleon Capital Management’s C4 Therapeutics CCCC Stock Holding History

Voleon Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,420
Closed -$63.1K – 818
2025
Q3 		$63.1K Buy
+28,420
New +$68.2K ﹤0.01% 867

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Voleon Capital Management's CCCC Position: Q4 2025 in Review

Voleon Capital Management sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 28,420 shares — an estimated $63.1K sold.

Voleon Capital Management first reported a position in CCCC in Q3 2025 and held it in 1 quarter. The position peaked at $63.1K in Q3 2025. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • Voleon Capital Management reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voleon Capital Management sold 28,420 C4 Therapeutics shares in Q4 2025, an estimated $63.1K.
  • Voleon Capital Management first reported a position in C4 Therapeutics in Q3 2025 and held it in 1 quarter.
  • Voleon Capital Management's C4 Therapeutics position peaked at $63.1K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Voleon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.